Changes in drug utilization during a gap in insurance coverage: An examination of the medicare part d coverage gap

PLoS Medicine

Volumn 8, Issue 8, 2011, Pages

  Polinski, Jennifer M ^a,b   Shrank, William H ^a,b   Huskamp, Haiden A ^b   Glynn, Robert J ^a,b,c   Liberman, Joshua N ^d   Schneeweiss, Sebastian ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d CVS Caremark   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT; GENERIC DRUG; ORAL ANTIDIABETIC AGENT; PRESCRIPTION DRUG;

AGED; ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DEMENTIA; DEPRESSION; DIABETES MELLITUS; DRUG SUBSTITUTION; DRUG UTILIZATION; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FINANCIAL MANAGEMENT; HAZARD RATIO; HEALTH INSURANCE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; INSURANCE; MAJOR CLINICAL STUDY; MALAISE; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDICARE; MUSCULOSKELETAL PAIN; PENSIONER; PRESCRIPTION; PREVALENCE; PROPENSITY SCORE; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; THORAX PAIN; COHORT ANALYSIS; COMPARATIVE STUDY; ECONOMICS; FEE; HEALTH CARE COST; HEALTH CARE PLANNING; PROPORTIONAL HAZARDS MODEL; STATISTICAL MODEL; UNITED STATES;

COHORT STUDIES; DRUG UTILIZATION; HEALTH EXPENDITURES; HEALTH PLANNING SUPPORT; HUMANS; INSURANCE COVERAGE; LOGISTIC MODELS; MEDICARE PART D; PRESCRIPTION DRUGS; PRESCRIPTION FEES; PROPORTIONAL HAZARDS MODELS; UNITED STATES;

EID: 80052305537     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001075     Document Type: Article

References (49)

1. Lee YC, Yang MC, Huang YT, Liu CH, Chen SB, (2006) Impacts of cost containment strategies on pharmaceutical expenditures of the National Health Insurance in Taiwan, 1996-2003. Pharmacoecon 24: 891-902.
2. Schneeweiss S, Walker AM, Glynn RJ, Maclure M, Dormuth C, et al. (2002) Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med 346: 822-829.
3. Polinski JM, Maclure M, Marshall B, Cassels A, Agnew-Blais J, et al. (2008) Does knowledge of medication prices predict physicians' support for cost effective prescribing policies. Can J Clin Pharmacol 15: e286-294.
4. Dormuth CR, Maclure M, Glynn RJ, Neumann P, Brookhart AM, et al. (2008) Emergency hospital admissions after income-based deductibles and prescription copayments in older users of inhaled medications. Clin Ther pp. 1038-1050 30 Spec No.
5. Kozyrskyj AL, Mustard CA, Cheang MS, Simons FE, (2001) Income-based drug benefit policy: impact on receipt of inhaled corticosteroid prescriptions by Manitoba children with asthma. CMAJ 165: 897-902.
6. Tamblyn R, Laprise R, Hanley JA, Abrahamowicz M, Scott S, et al. (2001) Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA 285: 421-429.
7. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, et al. (2003) The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med 349: 2224-2232.
8. Birkett DJ, Mitchell AS, McManus P, (2001) A cost-effectiveness approach to drug subsidy and pricing in Australia. Health Aff 20: 104-114.
9. Schoffski O, (1996) Consequences of implementing a drug budget for office-based physicians in Germany. Pharmacoecon 10: S37-S47.
10. Stewart-Brown S, Surender R, Bradlow J, Coulter A, Doll H, (1995) The effects of fund holding in general practice on prescribing habits three years after introduction of the scheme. BMJ 311: 1543-1547.
11. Soumerai SB, Avorn J, Ross-Degnan D, Gortmaker S, (1987) Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity. N Engl J Med 317: 550-556.
12. Centers for Medicare and Medicaid Services (2005) Medicare Program; Medicare Prescription Drug Benefit; Final Rule, 42 CFR 70, number 18.
13. Hoadley J, Hargrave E, Cubanski J, Neuman T, (2008) The Medicare Part D coverage gap: costs and consequences in 2007 Kaiser Family Foundation Available: http://www.kff.org/medicare/upload/7811.pdf Accessed 31 May 2011.
14. Powers C, (2008) Beneficiary experience. Part D data symposium. Baltimore (Maryland) Centers for Medicare and Medicaid Services (October 30).
15. Frist WH, (2005) Shattuck Lecture: health care in the 21st century. N Engl J Med 352: 267-272.
16. Goldman DP, Joyce GF, Zheng Y, (2007) Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA 298: 61-69.
17. Hsu J, Price M, Huang J, Brand R, Fung V, et al. (2006) Unintended consequences of caps on Medicare drug benefits. N Engl J Med 354: 2349-2359.
18. Joyce GF, Goldman DP, Karaca-Mandic P, Zheng Y, (2007) Pharmacy benefit caps and the chronically ill. Health Aff 26: 1333-1344.
19. Fung V, Mangione CM, Huang J, Turk N, Quiter ES, et al. (2010) Falling into the coverage gap: Part D drug costs and adherence for Medicare Advantage prescription drug plan beneficiaries with diabetes. Health Serv Res 45: 355-375.
20. Raebel MA, Delate T, Ellis JL, Bayliss EA, (2008) Effects of reaching the drug benefit threshold on Medicare members' healthcare utilization during the first year of Medicare Part D. Med Care 46: 1116-1122.
21. Schmittdiel JA, Ettner SL, Fung V, Huang J, Turk N, et al. (2009) Medicare Part D coverage gap and diabetes beneficiaries. Am J Manag Care 15: 189-193.
22. Zhang Y, Donohue JM, Newhouse JP, Lave JR, (2009) The effects of the coverage gap on drug spending: a closer look at Medicare Part D. Health Aff 28: w317-w325.
23. Cubanski J, Neuman P, (2007) Status report on Medicare Part D enrollment in 2006: analysis of plan-specific market share and coverage. Health Aff 26: w1-12.
24. Nesi T, (2010) CVS filled 1.3 billion prescriptions in '09. Providence (Rhode Island) Providence Business News.
25. Romano PS, Roos LL, Jollis JG, (1993) Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 46: 1075-1079; discussion 1081-1090.
26. Seeger JD, Walker AM, Williams PL, Saperia GM, Sacks FM, (2003) A propensity score-matched cohort study of the effect of statins, mainly fluvastatin, on the occurrence of acute myocardial infarction. Am J Cardiol 92: 1447-1451.
27. Steiner JF, Koepsell TD, Fihn SD, Inui TS, (1988) A general method of compliance assessment using centralized pharmacy records. Description and validation. Med Care 26: 814-823.
28. Choudhry NK, Shrank WH, Levin RL, Lee JL, Jan SA, et al. (2009) Measuring concurrent adherence to multiple related medications. Am J Manag Care 15: 457-464.
29. Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, et al. (2006) Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 355: 1525-1538.
30. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, et al. (2008) Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 148: 379-397.
31. Cox DR, (1972) Regression models and life tables (with discussion). J R Stat Soc 34: 187-220.
32. Fine JP, Gray RJ, (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94: 496-509.
33. Kim HT, (2007) Cumulative incidence in competing risks data and competing risks regression analysis. Clin Canc Res 13: 559-565.
34. Fitzmaurice G, Laird N, Ware J, (2004) Applied longitudinal analysis. Hoboken (New Jersey) John Wiley & Sons.
35. Heisler M, Langa KM, Eby EL, Fendrick AM, Kabeto MU, et al. (2004) The health effects of restricting prescription medication use because of cost. Med Care 42: 626-634.
36. Soumerai SB, Ross-Degnan D, Avorn J, McLaughlin T, Choodnovskiy I, (1991) Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med 325: 1072-1077.
37. Schneeweiss S, Schoffski O, Selke GW, (1998) What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution? Health Pol 44: 253-260.
38. Taxis K, Schneeweiss S, (2003) Frequency and predictors of drug therapy interruptions after hospital discharge under physician drug budgets in Germany. Internat J Clin Pharm Ther 41: 77-82.
39. Shrank WH, Hoang T, Ettner SL, Glassman PA, Nair K, et al. (2006) The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med 166: 332-337.
40. Schneeweiss S, Soumerai SB, Glynn RJ, Maclure M, Dormuth C, et al. (2002) Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization. CMAJ 166: 737-745.
41. Schneeweiss S, Dormuth C, Grootendorst P, Soumerai SB, Maclure M, (2004) Net health plan savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents. Med Care 42: 653-660.
42. Choudhry NK, Fischer MA, Avorn J, Schneeweiss S, Solomon DH, et al. (2010) At Pitney Bowes, value-based insurance design cut copayments and increased drug adherence. Health Aff 29: 1995-2001.
43. Chernew ME, Shah MR, Wegh A, Rosenberg SN, Juster IA, et al. (2008) Impact of decreasing copayments on medication adherence within a disease management environment. Health Aff 27: 103-112.
44. Schneeweiss S, (2006) Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 15: 291-303.
45. Suissa S, (2008) Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 167: 492-499.
46. Hargrave E, Piya B, Hoadley J, Summer L, Thompson J, (2008) Experiences obtaining drugs under Part D: focus groups with beneficiaries, physicians, and pharmacists. Available: http://www.medpac.gov/documents/May08_PartDFocusGroup_CONTRACTOR_JS.pdf. Accessed 10 August 2009.
47. Cronk A, Humphries TL, Delate T, Clark D, Morris B, (2008) Medication strategies used by Medicare beneficiaries who reach the Part D standard drug-benefit threshold. Am J Health-System Pharm 65: 1062-1070.
48. Hsu J, Fung V, Price M, Huang J, Brand R, et al. (2008) Medicare beneficiaries' knowledge of Part D prescription drug program benefits and responses to drug costs. JAMA 299: 1929-1936.
49. Hougaard P, (1999) Multi-state models: a review. Lifetime Data Analysis 5: 239-264.